Healthcare
Live Price
Offline$9.25
+2.21% today
1Y Change
+48.85%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 255 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sumitomo Pharma Co., Ltd. (SMDPY) is a Healthcare stock with a market cap of $687.11B and listed on OTC. The stock last traded around $9.25 and up 48.8% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +26.8%, EPS growth of +107.5%, a dividend yield of 0.0%. What stands out right now is revenue +26.8%, EPS +107.5%, free cash flow +101.3% with operating margin 12.9% and ROIC 9.7%. Valuation is more restrained than many high-expectation growth names at P/E 6.2 and price/sales 1.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SMDPY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SMDPY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SMDPY Max Drawdown
-62.91%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SMDPY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$516.0B
-7.9% YoY
FY Net Income
$56.2B
-0.3% YoY
Free Cash Flow
$124.8B
+603.3% YoY
Revenue Growth
+26.8%
EPS Growth
+107.5%
Gross Margin
59.2%
Net Margin
24.3%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 398.8B | 314.6B | 555.5B | 560.0B | 516.0B |
| Gross Profit | 245.4B | 188.0B | 376.6B | 402.9B | 378.2B |
| Operating Income | 28.8B | -354.2B | -77.0B | 60.2B | 71.2B |
| EBITDA | 56.7B | -281.1B | -3.5B | 124.4B | 103.1B |
| Net Income | 23.6B | -315.0B | -74.5B | 56.4B | 56.2B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 23.1B | 29.0B | 143.5B | 203.0B | 193.7B |
| Total Assets | 742.6B | 907.5B | 1134.7B | 1308.0B | 1308.1B |
| Total Liabilities | 573.1B | 751.4B | 728.0B | 634.4B | 659.9B |
| Shareholder Equity | 169.5B | 156.1B | 406.7B | 607.9B | 580.6B |
| Total Debt | 305.4B | 418.9B | 346.4B | 284.5B | 273.8B |
| Net Debt | 282.3B | 389.8B | 202.9B | 81.6B | 80.1B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
135.6B
+334.1% YoY
Capital Expenditures
10.8B
+19.9% YoY
Free Cash Flow
124.8B
+603.3% YoY
Key ratios
Gross Margin
59.2%
Operating Margin
12.9%
Net Margin
24.3%
ROE
48.9%
Debt / Equity
0.90x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.